Home
Home

dimebon

Pfizer, Medivation end development of potential Alzheimer's treatment dimebon

Pfizer, Medivation end development of potential Alzheimer's treatment dimebon
Yahoo/AP

3 Cancer-Fighting Stocks That Could Deliver Huge Gains

3 Cancer-Fighting Stocks That Could Deliver Huge Gains
Seeking Alpha

Medivation Remains Neutral

Medivation Remains Neutral
Yahoo/Zacks.com

Abiraterone vs. MDV3100: A prostate cancer drug showdown

Abiraterone vs. MDV3100: A prostate cancer drug showdown
Fierce Biotech

Medivation Shares Popped: What You Need to Know

Medivation Shares Popped: What You Need to Know
Motley Fool

Medivation/Pfizer drug fails late-stage Huntington's disease trial

Medivation/Pfizer drug fails late-stage Huntington's disease trial
Bizjournals.com

News

The Top 10 Phase III Failures of 2010
Fierce Biotech
»

News

Finkelstein Thompson LLP Announces Investigation of Medivation, Inc.
Yahoo/Business Wire
»

News

Pfizer's 3 Points of Failure
Motley Fool
»

News

Lesson from an Alzheimer-Drug Failure: Beware Russian Clinical Trial Data
BNET Pharma
»